Discrepancies association between FLT3 inhibitors use and prognosis of acute myeloid leukemia: systematic review and meta-analysis

Acute myeloid leukemia (AML) is a malignancy of proliferative, clonal, abnormally, or poorly differentiated cells of the hematopoietic system, characterized by clonal evolution and genetic heterogeneity. Mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur in approximately 30% of all AML cases, with the internal tandem duplication (ITD) representing the most common type of FLT3 mutation. FLT3-ITD is a common driver mutation that presents with a high leukemic burden and confers a poor prognosis in patients with AML. In this systematic review and meta-analysis, we present a detailed review of current clinical evidence of FLT3 inhibitors and their use in AML, and discrepancies association between FLT3 inhibitors use and prognosis of acute myeloid leukemia and maintenance setting.